Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
Clinical trial NCT04815356 · RECRUITING
Trial details
- NCT number
- NCT04815356
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-23
- Primary completion
- 2036-12-01
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.